A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer

被引：0
|
作者：
Bangyou Zuo
Xiaobo Yang
Xu Yang
Jin Bian
Junyu Long
Dongxu Wang
Cong Ning
Yanyu Wang
Ziyu Xun
Yunchao Wang
Xin Lu
Yilei Mao
Xinting Sang
Haitao Zhao
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC),Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Gallbladder cancer; PD-1; Lenvatinib; PD-L1 expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1889 / 1896
页数：7
相关论文
共 50 条
  • [41] Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
    Xu Yang
    Bowen Chen
    Yanyu Wang
    Yunchao Wang
    Junyu Long
    Nan Zhang
    Jingnan Xue
    Ziyu Xun
    Linzhi Zhang
    Jiamin Cheng
    Jin Lei
    Huishan Sun
    Yiran Li
    Jianzhen Lin
    Fucun Xie
    Dongxu Wang
    Jie Pan
    Ke Hu
    Mei Guan
    Li Huo
    Jie Shi
    Lingxiang Yu
    Lin Zhou
    Jinxue Zhou
    Zhenhui Lu
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Yinying Lu
    Haitao Zhao
    Hepatology International, 2023, 17 : 709 - 719
  • [42] Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population
    van Zeijl, M. C. T.
    Wouters, M. W. J. M.
    van den Eertwegh, A. J.
    Aarts, M. J.
    van Akkooi, A. C. J.
    van den Berkmortel, F. W. P. J.
    Franken, M. G.
    de Groot, J. W. B.
    Herbschleb, K. H.
    van der Hoeven, J. J. M.
    Hospers, G. A. P.
    Kapiteijn, E.
    Piersma, D.
    van Rijn, R. S.
    Suijkerbuijk, K. P. M.
    Ten Tije, A. J.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Haanen, J. B. A. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
    Cheon, Jaekyung
    Chon, Hong Jae
    Bang, Yeonghak
    Park, Neung Hwa
    Shin, Jung Woo
    Kim, Kang Mo
    Lee, Han Chu
    Lee, Jooho
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    LIVER CANCER, 2020, 9 (05) : 613 - 624
  • [44] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [45] Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
    Cheon, J.
    Yoo, C.
    Bang, Y.
    Chon, H.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1308 - S1308
  • [46] Anti-PD-1 therapy combined with chemotherapy or target therapy in patients with advanced biliary tract cancer in real-world clinical setting
    Sun, D.
    Ma, J.
    Han, C.
    Wang, J.
    Qian, Y.
    Chen, G.
    Li, X.
    Zhang, J.
    Song, J.
    Zhao, X.
    Cai, S.
    Hu, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 437 - 437
  • [47] Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer
    Mijin Kim
    Jonghwa Ahn
    Dong Eun Song
    Jee Hee Yoon
    Ho-Cheol Kang
    Dong Jun Lim
    Won Gu Kim
    Tae Yong Kim
    Won Bae Kim
    Young Kee Shong
    Min Ji Jeon
    Bo Hyun Kim
    Endocrine, 2021, 71 : 427 - 433
  • [48] Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer
    Kim, Mijin
    Ahn, Jonghwa
    Song, Dong Eun
    Yoon, Jee Hee
    Kang, Ho-Cheol
    Lim, Dong Jun
    Kim, Won Gu
    Kim, Tae Yong
    Kim, Won Bae
    Shong, Young Kee
    Jeon, Min Ji
    Kim, Bo Hyun
    ENDOCRINE, 2021, 71 (02) : 427 - 433
  • [49] Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
    Wang, Yunchao
    Yang, Xiaobo
    Wang, Yanyu
    Xue, Jingnan
    Zhang, Nan
    Yang, Xu
    Cong, Ning
    Zhang, Junwei
    Zhu, Chengpei
    Zhang, Longhao
    Hou, Xiaorong
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2197 - 2204
  • [50] Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
    Yunchao Wang
    Xiaobo Yang
    Yanyu Wang
    Jingnan Xue
    Nan Zhang
    Xu Yang
    Ning Cong
    Junwei Zhang
    Chengpei Zhu
    Longhao Zhang
    Xiaorong Hou
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2023, 72 : 2197 - 2204
12345